$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000143774922026628 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$2.001M	$2.252M	$2.366M
YoY Change	-16.73%	-4.82%	2.78%
Cost Of Revenue	$1.318M	$1.462M	$1.566M
YoY Change	-22.06%	-6.64%	2.69%
Gross Profit	$683.0K	$790.0K	$800.0K
YoY Change	-4.07%	-1.25%	2.96%
Gross Profit Margin	34.13%	35.08%	33.81%
Selling, General & Admin	$3.359M	$3.384M	$3.892M
YoY Change	-13.2%	-13.05%	12.45%
% of Gross Profit	491.8%	428.35%	486.5%
Research & Development	$1.146M	$1.086M	$1.397M
YoY Change	-18.03%	-22.26%	-1.41%
% of Gross Profit	167.79%	137.47%	174.63%
Depreciation & Amortization	$63.00K	$54.00K	$158.0K
YoY Change	-61.11%	-65.82%	-31.3%
% of Gross Profit	9.22%	6.84%	19.75%
Operating Expenses	$4.505M	$4.470M	$5.289M
YoY Change	-14.48%	-15.48%	8.43%
Operating Profit	-$3.822M	-$3.680M	-$4.489M
YoY Change	-16.11%	-18.02%	9.46%
Interest Expense	-$379.0K	$407.0K	$419.0K
YoY Change	-12.67%	-2.86%	-3.23%
% of Operating Profit
Other Income/Expense, Net	$19.00K		-$4.000K
YoY Change	-416.67%		-150.0%
Pretax Income	-$4.182M	-$4.087M	-$4.912M
YoY Change	-16.29%	-16.8%	8.43%
Income Tax
% Of Pretax Income
Net Earnings	-$5.311M	-$4.087M	-$4.912M
YoY Change	6.31%	-16.8%	8.55%
Net Earnings / Revenue	-265.42%	-181.48%	-207.61%
Basic Earnings Per Share		-$0.77	-$1.25
Diluted Earnings Per Share	-$0.70	-$601.2K	-$1.030M
COMMON SHARES
Basic Shares Outstanding	7.436M	7.040M	95.35M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.60M	$17.34M	$23.08M
YoY Change	-25.1%	-24.85%	-8.89%
Cash & Equivalents	$14.60M	$17.30M	$23.10M
Short-Term Investments
Other Short-Term Assets	$362.0K	$652.0K	$668.0K
YoY Change	20.67%	-2.4%	28.46%
Inventory	$4.965M	$5.047M	$4.519M
Prepaid Expenses
Receivables	$1.057M	$1.554M	$1.400M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.99M	$24.60M	$29.67M
YoY Change	-18.63%	-17.09%	-4.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$702.0K	$574.0K	$213.0K
YoY Change	638.95%	169.48%	-77.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$312.0K	$333.0K	$452.0K
YoY Change	-25.71%	-26.33%	-17.82%
Total Long-Term Assets	$3.208M	$3.356M	$4.073M
YoY Change	-13.16%	-17.6%	-29.3%
TOTAL ASSETS
Total Short-Term Assets	$20.99M	$24.60M	$29.67M
Total Long-Term Assets	$3.208M	$3.356M	$4.073M
Total Assets	$24.20M	$27.95M	$33.74M
YoY Change	-17.94%	-17.15%	-8.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$631.0K	$612.0K	$1.178M
YoY Change	-54.73%	-48.05%	86.39%
Accrued Expenses	$657.0K	$669.0K	$791.0K
YoY Change	-8.5%	-15.42%	15.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.17M		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$17.95M	$7.072M	$7.439M
YoY Change	281.34%	-4.93%	-58.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$13.67M	$11.85M
YoY Change	-100.0%	15.31%	1202.53%
Other Long-Term Liabilities	$1.001M	$881.0K	$431.0K
YoY Change	74.09%	104.41%	4688.89%
Total Long-Term Liabilities	$1.001M	$881.0K	$431.0K
YoY Change	74.09%	104.41%	4688.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.95M	$7.072M	$7.439M
Total Long-Term Liabilities	$1.001M	$881.0K	$431.0K
Total Liabilities	$20.05M	$23.01M	$22.17M
YoY Change	1.45%	3.76%	-1.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$402.4M	-$398.2M	-$379.8M
YoY Change	4.59%	4.84%	4.71%
Common Stock	$406.5M	$403.1M	$391.3M
YoY Change	3.05%	3.02%	3.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.146M	$4.946M	$11.57M
YoY Change
Total Liabilities & Shareholders Equity	$24.20M	$27.95M	$33.74M
YoY Change	-17.94%	-17.15%	-8.68%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$5.311M	-$4.087M	-$4.912M
YoY Change	6.31%	-16.8%	8.55%
Depreciation, Depletion And Amortization	$63.00K	$54.00K	$158.0K
YoY Change	-61.11%	-65.82%	-31.3%
Cash From Operating Activities	-$2.717M	-$3.496M	-$3.622M
YoY Change	-23.05%	-3.48%	10.76%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$0.00	$0.00
YoY Change	-225.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$20.00K	$0.00	$0.00
YoY Change	25.0%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.000K	4.799M	0.000
YoY Change	-94.12%		-100.0%
NET CHANGE
Cash From Operating Activities	-2.717M	-3.496M	-3.622M
Cash From Investing Activities	-20.00K	0.000	0.000
Cash From Financing Activities	-2.000K	4.799M	0.000
Net Change In Cash	-2.739M	1.303M	-3.622M
YoY Change	-23.51%	-135.97%	-141.25%
FREE CASH FLOW
Cash From Operating Activities	-$2.717M	-$3.496M	-$3.622M
Capital Expenditures	$20.00K	$0.00	$0.00
Free Cash Flow	-$2.737M	-$3.496M	-$3.622M
YoY Change	-22.13%	-3.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	Avinger Inc
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	241-7900
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Central Index Key EntityCentralIndexKey	0001506928
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	43000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2022Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	56366000	usd
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	56366000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7435644
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7435644
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4778263
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4778263
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	942000	usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	56451
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AVGR
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36817
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8873453
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Chesapeake Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7435644
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17342000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19497000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1554000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1393000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	5047000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4601000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	652000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	300000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	24595000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	25791000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2449000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	574000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	95000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	333000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	420000	usd
CY2022Q3	us-gaap	Assets Assets	27951000	usd
CY2021Q4	us-gaap	Assets Assets	29485000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	612000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1394000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1344000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1609000	usd
CY2022Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	3382000	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	669000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	718000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1065000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	985000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7072000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4706000	usd
CY2022Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	13668000	usd
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	12287000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1384000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	23005000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	19762000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	881000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	575000	usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1044000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	96000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	403133000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	394380000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398194000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384753000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4946000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9723000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27951000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29485000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2252000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2366000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6272000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7727000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1462000	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1566000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4301000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5015000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	790000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	800000	usd
	us-gaap	Gross Profit GrossProfit	1971000	usd
	us-gaap	Gross Profit GrossProfit	2712000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1086000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1397000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3244000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4502000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3384000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3892000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10862000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11755000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4470000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	5289000	usd
	us-gaap	Operating Expenses OperatingExpenses	14106000	usd
	us-gaap	Operating Expenses OperatingExpenses	16257000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3680000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4489000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12135000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13545000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	407000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	419000	usd
	us-gaap	Interest Expense InterestExpense	1286000	usd
	us-gaap	Interest Expense InterestExpense	1214000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2343000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4087000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4912000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13441000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12416000	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1127000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.78
	us-gaap	Share Based Compensation ShareBasedCompensation	960000	usd
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	1318000	usd
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	1151000	usd
	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	72000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3381000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3132000	usd
CY2022Q3	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature		usd
CY2021Q3	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature		usd
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	5111000	usd
	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature		usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5214000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5956000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21933000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15548000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.31
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6798000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4769000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5804000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4704000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	17282000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	239000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1044000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4912000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	11566000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	5321000	usd
CY2022Q3	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1127000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4087000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4946000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13076000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	960000	usd
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	3132000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12416000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	11566000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9723000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1000	usd
	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	usd
	avgr	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	127000	usd
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	3381000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13441000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4946000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13441000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12416000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	133000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	525000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	63000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	65000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	127000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	893000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19497000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22185000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17342000	usd
	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	102000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	156000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	97000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-37000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2155000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2353000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	198000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-82000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1182000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	733000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	352000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	318000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-15000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	44000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-783000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	484000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-265000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-324000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-49000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	122000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	306000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	431000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14043000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12166000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11919000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13077000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23078000	usd
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	3381000	usd
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	3132000	usd
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-72000	usd
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-102000	usd
	avgr	Transfers Between Inventory And Property And Equipment TransfersBetweenInventoryAndPropertyAndEquipment	580000	usd
	avgr	Transfers Between Inventory And Property And Equipment TransfersBetweenInventoryAndPropertyAndEquipment	-7000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b><em style="font: inherit;">1.</em> Organization</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Organization, Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <em style="font: inherit;"> March </em><em style="font: inherit;">2007.</em> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<em style="font: inherit;"> “OCT”) </em>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox consoles, as well as a variety of disposable catheter products. The Company’s current catheter products include Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Liquidity Matters</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <em style="font: inherit;"> September 30, 2022, </em>the Company had an accumulated deficit of $398.2 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $17.3 million at <em style="font: inherit;"> September 30, 2022 </em>and expected revenues from operations will be sufficient to allow the Company to fund its current operations partially through the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2023.</em> The Company received net proceeds of approximately $4.4 million from the sale of its common stock in <em style="font: inherit;"> August 2022, </em>$0.8 million from the sale of its common stock under an At The Market Offering Agreement during the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022, </em>$6.7 million from the <em style="font: inherit;"> January 2022 </em>Series D preferred stock equity financing and $13.0 million from the sale of its common stock in <em style="font: inherit;"> February 2021. </em>The Company <em style="font: inherit;"> may </em>seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">The Company can provide <em style="font: inherit;">no</em> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <em style="font: inherit;">not</em> create substantial dilution for its existing stockholders. Given the volatility in the Company’s stock price, any financing that the Company <em style="font: inherit;"> may </em>undertake in the next <em style="font: inherit;">twelve</em> months could cause substantial dilution to its existing stockholders, and there can be <em style="font: inherit;">no</em> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. In addition, the COVID-<em style="font: inherit;">19</em> pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <em style="font: inherit;"> may </em>have to significantly reduce its operations or delay, scale back or discontinue the development and sale of <em style="font: inherit;">one</em> or more of its products. The financial statements do <em style="font: inherit;">not</em> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Public Offerings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Past Offerings</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">On <em style="font: inherit;"> February 2, 2021, </em>under the shelf registration statement, the Company completed a bought deal offering of 500,000 shares of common stock at an offering price of $28.80 per share. As a result, the Company received aggregate net proceeds of approximately $13.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i><em style="font: inherit;"> January 2022 </em>Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">On <em style="font: inherit;"> January 14, 2022, </em>the Company entered into a securities purchase agreement with several institutional investors pursuant to which the Company agreed to sell and issue, in a registered direct offering (<em style="font: inherit;"> “January 2022 </em>Offering”), an aggregate of 7,600 shares of the Company’s Series D Convertible Preferred Stock, par value of $0.001 per share, at an offering price of $1,000 per share which was convertible into common stock at a conversion price of $8.00 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). As a result, the Company received aggregate net proceeds of approximately $6.7 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">The 807,500 Common Warrants have an exercise price of $9.60 per share and became exercisable beginning <em style="font: inherit;"> July 14, 2022. </em>The Common Warrants will expire <span style="-sec-ix-hidden:c90907233">five</span> years following the time they become exercisable, or <em style="font: inherit;"> July 14, 2027. </em>The Company also issued to the Placement Agent or its designees warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of <span style="-sec-ix-hidden:c90907236">five</span> years from the commencement of the sales pursuant to the <em style="font: inherit;"> January 2022 </em>Offering, or <em style="font: inherit;"> January 12, 2027.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i><em style="font: inherit;"> August 2022 </em>Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">On <em style="font: inherit;"> August 4, 2022, </em>the Company entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 1,484,019 shares of its common stock in a registered direct offering (“RD” or “Registered Direct”) at a purchase price of $1.752 per share, or pre-funded warrants in lieu thereof. In a concurrent private placement, the Company also agreed to issue and sell to the investor 1,369,864 shares of common stock at the same purchase price as in the registered direct offering, or pre-funded warrants in lieu thereof (“Private Placement” and together with the Registered Direct offering the <em style="font: inherit;"> “August 2022 </em>Offering”). As a result, the Company received aggregate net proceeds of approximately $4.4 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">As a result, in the Registered Direct offering, the Company issued (i) 700,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and in the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of 1,369,864 shares of common stock (the “Private Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the <em style="font: inherit;"> “August 2022 </em>Pre-Funded Warrants”).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">In addition, the Company issued to the investor in the <em style="font: inherit;"> August 2022 </em>Offering Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock (the “Preferred Investment Options”). The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire <span style="-sec-ix-hidden:c90907247">five</span> and <em style="font: inherit;">one</em>-half years from the date of issuance, or <em style="font: inherit;"> February 8, 2028, </em>and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire <span style="-sec-ix-hidden:c90907250">two</span> years from the date of issuance, or <em style="font: inherit;"> August 8, 2024. </em>The Company also issued to the Placement Agent or its designees preferred investment options to purchase up to an aggregate of 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of <span style="-sec-ix-hidden:c90907253">five</span> years from the commencement of the sales pursuant to the <em style="font: inherit;"> August 2022 </em>Offering, or <em style="font: inherit;"> August 3, 2027.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>At The Market Offering Agreement</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:36pt;">On <em style="font: inherit;"> May 20, 2022, </em>the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as sales agent, pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell shares of common stock, par value $0.001 per share (the “Shares”) up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Company’s shelf registration statement on Form S-<em style="font: inherit;">3,</em> which was initially filed with the Securities and Exchange Commission (the “SEC”) on <em style="font: inherit;"> March 29, 2022 </em>and declared effective on <em style="font: inherit;"> April 7, 2022, </em>and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on <em style="font: inherit;"> May 20, 2022. </em>During the quarter ended <em style="font: inherit;"> September 30, 2022, </em>the Company sold 259,137 shares of common stock at an average price of $1.56 per share for aggregate proceeds of $0.4 million, of which approximately $12,000 was paid in the form of commissions to the Agent. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022, </em>the Company sold 585,603 shares of common stock pursuant to the ATM Agreement at an average price of $1.67 per share for aggregate proceeds of $1.0 million, of which approximately $29,000 was paid in the form of commissions to the Agent. Other than the ATM Agreement, the Company currently does <em style="font: inherit;">not</em> have any commitments to obtain additional funds. On <em style="font: inherit;"> August 3, 2022, </em>the Company suspended sales under the ATM Agreement. While the Company <em style="font: inherit;"> may </em>resume sales in the future, there can be <em style="font: inherit;">no</em> assurance that the Company will be successful in acquiring additional funding through these means.</p>
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398200000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17300000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	137000	usd
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	231000	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	187000	usd
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	193000	usd
CY2022Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	6000	usd
CY2021Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	5000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	10000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	46000	usd
CY2022Q3	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	34000	usd
CY2021Q3	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	40000	usd
CY2022Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	109000	usd
CY2021Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	196000	usd
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	88000	usd
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	43000	usd
CY2022Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	109000	usd
CY2021Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	196000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4601000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5214000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5956000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21933000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15548000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6798000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4769000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5804000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4704000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.31
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5605361
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	205674
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2557846
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	209468
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2863000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2503000	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	333000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1851000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2097000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	5047000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3179000	usd
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5800000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065	pure
	avgr	Operating Lease Expense Excluding Maintenance Fee And Other Expense Monthly OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly	105000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	942000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	63000	usd
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	59000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	200000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	177000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	271000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	256000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	802000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	758000	usd
CY2022Q3	us-gaap	Prepaid Rent PrepaidRent	86000	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	158000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	293000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1203000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1138000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2634000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	185000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2449000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2449000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2449000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3179000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1065000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	985000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1384000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2194000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2449000	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	56451
	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	5111000	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7435644
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26456895
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	132265
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	51582758
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	8652148
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	8652148
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	132265
CY2022Q3	us-gaap	Share Price SharePrice	1.15
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	239000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	127000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	960000	usd

Files In Submission

Name	View Source	Status
avgr-20220930_cal.xml	Edgar Link	unprocessable
0001437749-22-026628-index-headers.html	Edgar Link	pending
0001437749-22-026628-index.html	Edgar Link	pending
0001437749-22-026628.txt	Edgar Link	pending
0001437749-22-026628-xbrl.zip	Edgar Link	pending
avgr-20220930.xsd	Edgar Link	pending
avgr20220930_10q.htm	Edgar Link	pending
ex_442420.htm	Edgar Link	pending
ex_442421.htm	Edgar Link	pending
ex_442422.htm	Edgar Link	pending
ex_444647.htm	Edgar Link	pending
ex_444648.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
avgr-20220930_def.xml	Edgar Link	unprocessable
avgr-20220930_lab.xml	Edgar Link	unprocessable
avgr-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
avgr20220930_10q_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2022 Q4 Form 10-Q Financial Statement

#000143774922026628 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2022 Q4 Form 10-Q Financial Statement

#000143774922026628 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr